BD and Opentrons Labworks announced a multi‑year collaboration on October 8, 2025, to integrate Opentrons’ liquid‑handling robots with BD’s single‑cell multiomics instruments. The partnership will enable automation of critical experimental steps—including next‑generation sequencing library preparation and cell capture—for BD’s Rhapsody HT Xpress System.
The collaboration will develop an automation‑compatible module for the Rhapsody system, allowing hands‑free workflows, and will create verified protocols for labs. Early‑access opportunities will be available at the American Society of Human Genetics (ASHG) Annual Meeting in Boston, October 14‑18, 2025.
By automating multiomics workflows, BD can increase throughput and reproducibility, potentially driving higher adoption of its Rhapsody platform and generating new revenue streams. The partnership aligns with BD’s BD 2025 strategy to enhance operational efficiency and innovation, expanding BD’s footprint in oncology, immunology, and other research fields.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.